Progressive Multifocal Leukoencephalopathy: Current Insights

Marge Kartau, Jussi O. T. Sipilä, Eeva Auvinen, Maarit Palomäki, Auli Verkkoniemi-Ahola

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

Sammanfattning

Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.

Originalspråkengelska
TidskriftNeurodegenerative Diseases
Volym9
Sidor (från-till)109-121
Antal sidor13
ISSN1660-2854
DOI
StatusPublicerad - 2 dec 2019
MoE-publikationstypA2 Granska artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

  • 3124 Neurologi och psykiatri

Citera det här

Kartau, Marge ; Sipilä, Jussi O. T. ; Auvinen, Eeva ; Palomäki, Maarit ; Verkkoniemi-Ahola, Auli. / Progressive Multifocal Leukoencephalopathy: Current Insights. I: Neurodegenerative Diseases. 2019 ; Vol. 9. s. 109-121.
@article{8e6559fb4a6e4610ab4afae646167d13,
title = "Progressive Multifocal Leukoencephalopathy: Current Insights",
abstract = "Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.",
keywords = "3124 Neurology and psychiatry, progressive multifocal leukoencephalopathy, JC polyomavirus, monoclonal antibodies, HIV, multiple sclerosis, disease modifying therapies, SYSTEMIC-LUPUS-ERYTHEMATOSUS, MULTIPLE-SCLEROSIS, JC-VIRUS, CELL TRANSPLANTATION, RISK, PML, THERAPY, DISORDERS, INFECTION, SURVIVAL",
author = "Marge Kartau and Sipil{\"a}, {Jussi O. T.} and Eeva Auvinen and Maarit Palom{\"a}ki and Auli Verkkoniemi-Ahola",
year = "2019",
month = "12",
day = "2",
doi = "10.2147/DNND.S203405",
language = "English",
volume = "9",
pages = "109--121",
journal = "Neurodegenerative Diseases",
issn = "1660-2854",
publisher = "Karger",

}

Progressive Multifocal Leukoencephalopathy: Current Insights. / Kartau, Marge; Sipilä, Jussi O. T.; Auvinen, Eeva; Palomäki, Maarit ; Verkkoniemi-Ahola, Auli.

I: Neurodegenerative Diseases, Vol. 9, 02.12.2019, s. 109-121.

Forskningsoutput: TidskriftsbidragÖversiktsartikelVetenskapligPeer review

TY - JOUR

T1 - Progressive Multifocal Leukoencephalopathy: Current Insights

AU - Kartau, Marge

AU - Sipilä, Jussi O. T.

AU - Auvinen, Eeva

AU - Palomäki, Maarit

AU - Verkkoniemi-Ahola, Auli

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.

AB - Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.

KW - 3124 Neurology and psychiatry

KW - progressive multifocal leukoencephalopathy

KW - JC polyomavirus

KW - monoclonal antibodies

KW - HIV

KW - multiple sclerosis

KW - disease modifying therapies

KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS

KW - MULTIPLE-SCLEROSIS

KW - JC-VIRUS

KW - CELL TRANSPLANTATION

KW - RISK

KW - PML

KW - THERAPY

KW - DISORDERS

KW - INFECTION

KW - SURVIVAL

U2 - 10.2147/DNND.S203405

DO - 10.2147/DNND.S203405

M3 - Review Article

VL - 9

SP - 109

EP - 121

JO - Neurodegenerative Diseases

JF - Neurodegenerative Diseases

SN - 1660-2854

ER -